Correct coding is the responsibility of the provider submitting a claim for the item or service. Here we provide general billing and coding information for LENVIMA® (lenvatinib) and related services. Please check with the payor to verify coding or special billing requirements.
LENVIMA® (lenvatinib) is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), in combination with everolimus for the treatment of patients with unresectable advanced or metastic renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, and for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Providers should use current ICD-10-CM codes to report a patient's diagnosis on claim submissions. Below is a list of ICD-10-CM diagnosis codes that may be reasonably related to a diagnosis within the product's approved label. Other codes may be appropriate.
Correct coding is the responsibility of the provider submitting a claim for the item or service. Please see FDA approved indications for LENVIMA® (lenvatinib) and check with the payor to verify coding or special billing requirements.
ICD-10-CM Diagnosis Code |
Description |
C22.0 |
Liver cell carcinoma, hepatocellular carcinoma, hepatoma |
C22.9 |
Malignant neoplasm of liver, not specified as primary or secondary |
C73 |
Malignant neoplasm of thyroid gland |
C64 |
Malignant neoplasm of kidney, except renal pelvis |
C64.1 |
Malignant neoplasm of right kidney, except renal pelvis |
C64.2 |
Malignant neoplasm of left kidney, except renal pelvis |
C64.9 |
Malignant neoplasm of unspecified kidney, except renal pelvis |
The National Drug Code is a unique 10-digit, 3-segment numeric identifier assigned to each medication listed under Section 510 of the US Federal Food, Drug, and Cosmetic Act. The NDC number identifies the labeler, product, and trade package size. LENVIMA® has been assigned the following NDC numbers based on the different available package sizes.
NDC number |
LENVIMA® daily-dose carton |
NDC number |
Capsules per 5-day card |
NDC 62856-724-30 |
24 mg |
NDC 62856-724-05 |
Ten 10 mg and five 4 mg capsules |
NDC 62856-720-30 |
20 mg |
NDC 62856-720-05 |
Ten 10 mg capsules |
NDC 62856-718-30 |
18 mg |
NDC 62856-718-05 |
Five 10 mg capsules and ten 4 mg capsules |
NDC 62856-714-30 |
14 mg |
NDC 62856-714-05 |
Five 10 mg capsules and five 4 mg capsules |
NDC 62856-712-30 |
12 mg |
NDC 62856-712-05 |
Fifteen 4 mg capsules |
NDC 62856-710-30 |
10 mg |
NDC 62856-710-05 |
Five 10 mg capsules |
NDC 62856-708-30 |
8 mg |
NDC 62856-708-05 |
Ten 4 mg capsules |
NDC 62856-704-30 |
4 mg |
NDC 62856-704-05 |
Five 4 mg capsules |
Some payors require physicians to report 11-digit NDCs when reporting a drug on a claim form. Converting the 10-digit NDC for LENVIMA® to an 11-digit NDC requires the use of a leading zero in the product code section of the NDC (i.e., the middle section):
10-Digit NDC Example |
11-Digit NDC Example with Leading Zero |
AAAAA-BBB-CC |
AAAAA-0BBB-CC |
LENVIMA® 10-Digit NDC |
LENVIMA® 11-Digit NDC with Leading Zero |
62856-724-30 |
62856-0724-30 |
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
LENVIMA is indicated:
For more information about LENVIMA please see available full Prescribing Information.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.
LENVIMA® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.
LENV-US5366